University of Patras
Σύνθεση καινοτόμων αγωνιστών του υποδοχέα B2 της βραδυκινίνης με στόχο την ανάπτυξη αντικαρκινικών φαρμάκων
Abstract
dc:descriptionBradykinin (BK) is a nonapeptide hormone (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) that plays a critical role in various physiological processes, including cardiovascular homeostasis, inflammatory responses, and pain transmission. Its biological effects are mediated through the activation of two receptors, B1 and B2. Moreover, recent studies have indicated that BK may contribute to tumor progression, making its receptors potential targets for the development of anticancer agents. Initially, the scientific literature suggested that only antagonists of B1R and B2R could exert antiproliferative effects. However, more recent evidence has revealed that B1R agonists may also display such effects, sparking renewed interest in this research area. This raises the question of whether a B2R agonist could induce more pronounced antiproliferative effects, given the broader expression of the B2 receptor in various tissues. Most agonists described to date are peptide-based, although selective non-peptide B2R agonists have also been developed. In our laboratory, the agonist FR-190997 was synthesized and evaluated in breast cancer cell lines, including triple-negative forms, confirming its potent anticancer activity. Recent findings have shown that FR-190997 exerts strong antiproliferative effects via B2R activation, with an EC₅₀ of 80 nM in the MDA-MB-231 cell line, demonstrating superior efficacy compared to several approved breast cancer drugs. Based on these findings, a research program was developed with two main objectives: (a) the synthesis of sufficient quantities of FR-190997 for further in vitro and in vivo studies, as well as its potential repositioning in various cancer types, and (b) the development of novel analogues for structure-activity relationship (SAR) studies. The multistep synthesis of FR-190997 posed a significant challenge, as the original method involved 20 steps, 13 of which required chromatographic purification. Through optimization, a new 17-step method was developed, free of chromatographic purification, enabling the production of multigram quantities of FR-190997 and the synthesis of 55 new analogues. FR-190997 and several of its innovative analogues were found to exhibit excellent anticancer activity in cancer cell lines of breast cancer (MCFix 7, MDA-MB-231) and lung cancer (A549), glioblastoma (U87-MG), and melanoma (SK-MEL-28), with EC₅₀ values of 1–40 nM.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vachlioti, Eleana
- Βαχλιώτη, Ελεάνα
Subjects
dc:subject × 24- Καρκίνος μαστού
- Καρκίνος πνεύμονα
- Γλοιοβλάστωμα
- Μελάνωμα
- Βραδυκινίνη
- Υποδοχέας Β2
- Εκλεκτικός μη-πεπτιδικός αγωνιστής
- FR 190997
- Κινναμικά οξέα
- Breast cancer
- Lung cancer
- Glioblastoma
- Melanoma
- Bradykinin
- B2 receptor
- Selective non-peptide agonist
- FR-190997
- Cinnamic acids
- Χημεία
- Φυσικές Επιστήμες
- Οργανική χημεία
- Chemical Sciences
- Natural Sciences
- Organic Chemistry
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60856